Enhancing Australia’s Health Technology Assessment through Robust Horizon Scanning

Medicines Australia emphasizes the critical role of comprehensive horizon scanning in reforming Australia’s Health Technology Assessment (HTA) system. CEO Liz de Somer highlights that inadequate horizon scanning over the past decade has led to delays in patient access to innovative therapies, as the Pharmaceutical Benefits Advisory Committee (PBAC) struggles with increasing submission volumes and complexity. The HTA Review identifies the need for a well-resourced horizon scanning function to improve stakeholder engagement and support healthcare planning. Implementing such a process is essential to prepare Australia’s regulatory and reimbursement systems for upcoming medical breakthroughs, ensuring timely patient access to new treatments.

As a founding partner of InGeNA, Medicines Australia plays a pivotal role in advancing the integration of genomics into healthcare. Our ongoing collaboration underscores a shared commitment to fostering innovation and ensuring Australians benefit from cutting-edge medical breakthroughs. Medicines Australia’s expertise in shaping health technology assessment reforms aligns seamlessly with InGeNA’s vision of equitable and timely access to genomic advancements, highlighting the strength of industry partnerships in driving transformative healthcare initiatives.

Read the full article on Medicines Australia’s website

Stay informed about developments in genomics by following InGeNA for more updates on the worldwide genomics industry.